The global Biologics and Biosimilars market size was valued at US$ 454100 million in 2024 and is forecast to a readjusted size of USD 797670 million by 2031 with a CAGR of 8.5% during review period.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
This report is a detailed and comprehensive analysis for global Biologics and Biosimilars market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biologics and Biosimilars market size and forecasts, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biologics and Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biologics and Biosimilars market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Biologics and Biosimilars market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
麻豆原创 segment by Application
Hospital
Retail Pharmacy
Other
麻豆原创 segment by players, this report covers
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biologics and Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biologics and Biosimilars, with revenue, gross margin, and global market share of Biologics and Biosimilars from 2020 to 2025.
Chapter 3, the Biologics and Biosimilars competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Biologics and Biosimilars market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics and Biosimilars.
Chapter 13, to describe Biologics and Biosimilars research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Biologics and Biosimilars by Type
1.3.1 Overview: Global Biologics and Biosimilars 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Biologics and Biosimilars Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Monoclonal Antibodies
1.3.4 Interferon
1.3.5 Insulin
1.3.6 Vaccines
1.3.7 Others
1.4 Global Biologics and Biosimilars 麻豆原创 by Application
1.4.1 Overview: Global Biologics and Biosimilars 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Biologics and Biosimilars 麻豆原创 Size & Forecast
1.6 Global Biologics and Biosimilars 麻豆原创 Size and Forecast by Region
1.6.1 Global Biologics and Biosimilars 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Biologics and Biosimilars 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Biologics and Biosimilars 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Biologics and Biosimilars 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Biologics and Biosimilars 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Biologics and Biosimilars 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Biologics and Biosimilars Product and Solutions
2.1.4 Roche Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Biologics and Biosimilars Product and Solutions
2.2.4 Amgen Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Amgen Recent Developments and Future Plans
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Biologics and Biosimilars Product and Solutions
2.3.4 AbbVie Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 AbbVie Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Biologics and Biosimilars Product and Solutions
2.4.4 Sanofi Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Biologics and Biosimilars Product and Solutions
2.5.4 Johnson & Johnson Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Biologics and Biosimilars Product and Solutions
2.6.4 Pfizer Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Biologics and Biosimilars Product and Solutions
2.7.4 Novo Nordisk Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Biologics and Biosimilars Product and Solutions
2.8.4 Eli Lilly Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Biologics and Biosimilars Product and Solutions
2.9.4 Novartis Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Biologics and Biosimilars Product and Solutions
2.10.4 Merck Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Merck Recent Developments and Future Plans
2.11 Biogen
2.11.1 Biogen Details
2.11.2 Biogen Major Business
2.11.3 Biogen Biologics and Biosimilars Product and Solutions
2.11.4 Biogen Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Biogen Recent Developments and Future Plans
2.12 Celltrion
2.12.1 Celltrion Details
2.12.2 Celltrion Major Business
2.12.3 Celltrion Biologics and Biosimilars Product and Solutions
2.12.4 Celltrion Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Celltrion Recent Developments and Future Plans
2.13 Sobi
2.13.1 Sobi Details
2.13.2 Sobi Major Business
2.13.3 Sobi Biologics and Biosimilars Product and Solutions
2.13.4 Sobi Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Sobi Recent Developments and Future Plans
2.14 3SBIO
2.14.1 3SBIO Details
2.14.2 3SBIO Major Business
2.14.3 3SBIO Biologics and Biosimilars Product and Solutions
2.14.4 3SBIO Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 3SBIO Recent Developments and Future Plans
2.15 Changchun High Tech
2.15.1 Changchun High Tech Details
2.15.2 Changchun High Tech Major Business
2.15.3 Changchun High Tech Biologics and Biosimilars Product and Solutions
2.15.4 Changchun High Tech Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Changchun High Tech Recent Developments and Future Plans
2.16 Kanghong Pharma
2.16.1 Kanghong Pharma Details
2.16.2 Kanghong Pharma Major Business
2.16.3 Kanghong Pharma Biologics and Biosimilars Product and Solutions
2.16.4 Kanghong Pharma Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Kanghong Pharma Recent Developments and Future Plans
2.17 Innovent Biologics
2.17.1 Innovent Biologics Details
2.17.2 Innovent Biologics Major Business
2.17.3 Innovent Biologics Biologics and Biosimilars Product and Solutions
2.17.4 Innovent Biologics Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Innovent Biologics Recent Developments and Future Plans
2.18 Gan&Lee
2.18.1 Gan&Lee Details
2.18.2 Gan&Lee Major Business
2.18.3 Gan&Lee Biologics and Biosimilars Product and Solutions
2.18.4 Gan&Lee Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Gan&Lee Recent Developments and Future Plans
2.19 Tonghua Dongbao
2.19.1 Tonghua Dongbao Details
2.19.2 Tonghua Dongbao Major Business
2.19.3 Tonghua Dongbao Biologics and Biosimilars Product and Solutions
2.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 Tonghua Dongbao Recent Developments and Future Plans
2.20 United Laboratory
2.20.1 United Laboratory Details
2.20.2 United Laboratory Major Business
2.20.3 United Laboratory Biologics and Biosimilars Product and Solutions
2.20.4 United Laboratory Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 United Laboratory Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Biologics and Biosimilars Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Biologics and Biosimilars by Company Revenue
3.2.2 Top 3 Biologics and Biosimilars Players 麻豆原创 Share in 2024
3.2.3 Top 6 Biologics and Biosimilars Players 麻豆原创 Share in 2024
3.3 Biologics and Biosimilars 麻豆原创: Overall Company Footprint Analysis
3.3.1 Biologics and Biosimilars 麻豆原创: Region Footprint
3.3.2 Biologics and Biosimilars 麻豆原创: Company Product Type Footprint
3.3.3 Biologics and Biosimilars 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Biologics and Biosimilars Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Biologics and Biosimilars 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Biologics and Biosimilars Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Biologics and Biosimilars 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Biologics and Biosimilars Consumption Value by Type (2020-2031)
6.2 North America Biologics and Biosimilars 麻豆原创 Size by Application (2020-2031)
6.3 North America Biologics and Biosimilars 麻豆原创 Size by Country
6.3.1 North America Biologics and Biosimilars Consumption Value by Country (2020-2031)
6.3.2 United States Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Biologics and Biosimilars Consumption Value by Type (2020-2031)
7.2 Europe Biologics and Biosimilars Consumption Value by Application (2020-2031)
7.3 Europe Biologics and Biosimilars 麻豆原创 Size by Country
7.3.1 Europe Biologics and Biosimilars Consumption Value by Country (2020-2031)
7.3.2 Germany Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Biologics and Biosimilars 麻豆原创 Size by Region
8.3.1 Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2020-2031)
8.3.2 China Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Biologics and Biosimilars Consumption Value by Type (2020-2031)
9.2 South America Biologics and Biosimilars Consumption Value by Application (2020-2031)
9.3 South America Biologics and Biosimilars 麻豆原创 Size by Country
9.3.1 South America Biologics and Biosimilars Consumption Value by Country (2020-2031)
9.3.2 Brazil Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size by Country
10.3.1 Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2020-2031)
10.3.2 Turkey Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Biologics and Biosimilars 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Biologics and Biosimilars 麻豆原创 Drivers
11.2 Biologics and Biosimilars 麻豆原创 Restraints
11.3 Biologics and Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Biologics and Biosimilars Industry Chain
12.2 Biologics and Biosimilars Upstream Analysis
12.3 Biologics and Biosimilars Midstream Analysis
12.4 Biologics and Biosimilars Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
听
听
*If Applicable.
